Table 5: Immunohistochemistry analysis of biopsy samples (n=9).hENT1: Human equilibrative nucleoside transporter 1; RRM: Ribonucleotide reductase subunit M; TK1: Thymidine kinase 1; HUR: human antigen R; Ki67: protein Ki-67.

 

No Expression

Mild Expression

Moderate Expression

High Expression

Benefit prediction of gemcitabine-based chemotherapy (logistic regression) p-value)

hENT1

1 (11.1%)

3 (33.3%)

4 (44.4%)

1 (11.1%)

0.438

RRM

1 (11.1%)

6 (66.7%)

2 (22.2%)

0 (0%)

0.399

TK1

0 (0%)

3 (33.3%)

2 (22.2%)

4 (44.4%)

0.181

HUR

0 (0%)

1 (11.1%)

3 (33.3%)

5 (55.6%)

-

Ki67 Median

(95%CI) (range)

15 (10-20)

(5-70)

-

-

-

-